Featured
Brain activity when we act unconsciously studied
Patient Briefs Jul 31, 2026
Patient Briefs Jul 31, 2026
Patient Briefs Jul 30, 2026
Philips recovers from US trade tariffs hit on medical devices with a €186 million refund,...
Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when...
Heart failure management is shifting as pharmacists take on a larger role. Discover how they...
Read our latest NF Research articles.
Discover how your mind operates beyond awareness with surprising neurological insights and real-life examples.
Edwards sees boost in heart valve sales driven by increasing demand for TAVR devices and...
Explore the 2026 pulmonary embolism guidelines released by the American Heart Association and ACC, detailing...
Research sheds light on brain activity when we act unconsciously, studying awareness in actions with high confidence.
Research sheds light on brain activity when we act unconsciously, studying awareness in actions with high confidence.
New research reveals a severe wildfire risk facing American landmarks. Over half of historic sites are exposed to dangerous burns....
Discover the portable fat burning breath device that tracks metabolic shifts by measuring acetone in exhaled air, providing a lab‑free...
Discover how your mind operates beyond awareness with surprising neurological insights and real-life examples.
Discover the molecular signals guiding kidney immune cells to rebuild defenses after injury. Learn how these systems work to recover...
Philips recovers from US trade tariffs hit on medical devices with a €186 million refund, nearly half of its net...
Freenome wins approval for cancer blood test, a new screening method for colorectal cancer diagnosis.
Johnson & Johnson gets FDA approval for Ottava robot to compete with da Vinci in soft tissue surgery systems.
Philips secures FDA approval for a new pulse oximeter addressing racial bias with improved accuracy across skin tones.
Tempus AI agrees to buy Personalis for $1.5 billion to enhance cancer diagnostics and treatment selection with molecular residual disease...